EXOGENUS THERAPEUTICS SA

Their core work

Exogenus Therapeutics is a Portuguese biotech SME built around a single, focused platform: engineered exosomes — naturally occurring extracellular vesicles — used as therapeutic agents to treat human disease. Their work spans skin repair and wound healing (HEXKIN, 2016) through to autoimmune disease management (TEXAD, 2019), with exosomes serving as the core mechanism across both programs. As coordinator on both EU projects rather than a participant, they drive their own R&D agenda rather than serving as a subcontractor to larger institutions. Based in Cantanhede, home to Portugal's Biocant biotech park, they operate inside a cluster environment designed to support exactly this kind of translational biotech development.

What they specialise in

How they've shifted over time

Their first EU project (HEXKIN, 2016) was a tightly scoped feasibility study on exosomes for skin repair — a well-defined, contained indication well-suited to a Phase 1 SME grant. By 2019, TEXAD shows a deliberate move into autoimmune diseases, which is a significantly larger, more complex, and more commercially valuable therapeutic category. This progression follows a classic biotech platform-building trajectory: validate the technology in one indication, then demonstrate its broader applicability to attract licensing partners or larger clinical collaborators.

Exogenus Therapeutics is expanding their exosome platform from a narrow dermatology application toward broader systemic disease indications, suggesting they are building toward clinical-stage development or licensing partnerships in immunology and regenerative medicine.

How they like to work

Exogenus has acted as coordinator on both H2020 projects, and the data records no consortium partners — consistent with SME Phase 1 (SME-1) grants, which are typically solo feasibility studies rather than multi-partner collaborations. This means they have hands-on experience leading EU grant processes but a limited track record of working within large consortia. For a potential partner, this suggests an autonomous, self-directed team that may be newer to the dynamics of multi-partner EU projects, but brings the scientific focus of a company that has not had to divide its attention across consortium management.

No consortium partners are recorded across their two H2020 projects, which reflects the structure of SME-1 (Phase 1) grants rather than necessarily a preference for isolation. Their effective European research network at this stage appears limited, centered on their immediate Portuguese biotech cluster in Cantanhede.

What sets them apart

Exogenus Therapeutics occupies a rare niche: a small Portuguese biotech focused entirely on exosomes as a therapeutic platform rather than merely a delivery vehicle within someone else's drug program. With EU-validated proof-of-concept in both skin conditions and autoimmune diseases, they offer a platform technology that is specific enough to be immediately actionable for consortium builders in immunotherapy or regenerative medicine. Few SMEs in Southern Europe bring this combination of a dedicated exosome platform and two coordinated EU grant validations behind it.

Highlights from their portfolio

• TEXAD
  The larger of their two grants (€115,000) and a clear signal of strategic ambition — expanding the exosome platform into autoimmune diseases, a far broader commercial market than skin repair.
• HEXKIN
  Their founding EU project, establishing the first proof-of-concept for exosome-based skin healing and providing the scientific baseline for all subsequent platform development.